Evidence map›Paper›PMID 36985704›Full record

ReviewMolecules (Basel, Switzerland)2023

Recent Development of Rhenium-Based Materials in the Application of Diagnosis and Tumor Therapy.

Qingwen Qi, Qian Wang, Yuhao Li, Dionisio Zaldivar Silva, Maria Eliana Lanio Ruiz, Ruizhuo Ouyang, Baolin Liu, Yuqing Miao

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Rhenium-186-labeledRSC advances · 2026
    Article
  2. Article
  3. Early Transition Metal-Based Antitumor Complexes.Chemistry, an Asian journal · 2026
    Review
  4. Photophysical and Time-resolved Infrared Properties of Long-Lived Rhenium(I) 4,5-Diazafluorene Tricarbonyl Chromophores.Chemphyschem : a European journal of chemical physics and physical chemistry · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qingwen QiSchool of Materials and Chemistry, Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai 200093, China.
Qian WangSchool of Materials and Chemistry, Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai 200093, China.
Yuhao LiSchool of Materials and Chemistry, Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai 200093, China.ORCID 0000-0001-7146-8645
Dionisio Zaldivar SilvaUSST-UH International Joint Laboratory for Tumor Diagnosis and Energy Treatment, University of Shanghai for Science and Technology, Shanghai 200093, China.ORCID 0000-0003-1266-0877
Maria Eliana Lanio RuizUSST-UH International Joint Laboratory for Tumor Diagnosis and Energy Treatment, University of Shanghai for Science and Technology, Shanghai 200093, China.
Ruizhuo OuyangSchool of Materials and Chemistry, Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai 200093, China.ORCID 0000-0001-5091-6816
Baolin LiuUSST-UH International Joint Laboratory for Tumor Diagnosis and Energy Treatment, University of Shanghai for Science and Technology, Shanghai 200093, China.
Yuqing MiaoSchool of Materials and Chemistry, Institute of Bismuth and Rhenium, University of Shanghai for Science and Technology, Shanghai 200093, China.

Funding

the Natural Science Foundation of Shanghai 19ZR1434700
6 · The paper itself

Abstract

Rhenium (Re) is widely used in the diagnosis and treatment of cancer due to its unique physical and chemical properties. Re has more valence electrons in its outer shell, allowing it to exist in a variety of oxidation states and to form different geometric configurations with many different ligands. The luminescence properties, lipophilicity, and cytotoxicity of complexes can be adjusted by changing the ligand of Re. This article mainly reviews the development of radionuclide

Indexed as

NeoplasmsRheniumHumansLigandsLuminescenceOxidation-ReductionRadioisotopesLigandsRadioisotopesRheniumcancer therapycomplexesimagingnanomaterialsrhenium

Identifiers

PMID36985704
PMCPMC10051626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.